Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cebranopadol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 20/20 | 0.86 |
| ▸ | OPRL1 known ✓ | P41146 | 7/20 | 0.86 |
| ▸ | OPRD1 known ✓ | P41143 | 3/20 | 0.86 |
| ▸ | OPRK1 known ✓ | P41145 | 3/20 | 0.86 |
| ▸ | OGFRL1 | Q5TC84 | 16/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cebranopadol SCHEMBL154336 | 0.93 | OPRM1 (1.00) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| Cebranopadol SCHEMBL566256 | 0.93 | OPRM1 (1.00) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| Cebranopadol SCHEMBL10035739 | 0.93 | OPRM1 (1.00) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| Cebranopadol SCHEMBL29353179 | 0.93 | OPRM1 (1.00) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| Cebranopadol SCHEMBL15007659 | 0.92 | OPRM1 (0.98) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| Cebranopadol SCHEMBL15007271 | 0.91 | OPRM1 (0.89) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| Cebranopadol SCHEMBL29597164 | 0.87 | OPRM1 (0.77) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| SCHEMBL682517 | 0.83 | OPRM1 (1.00) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| SCHEMBL682578 | 0.82 | OPRM1 (1.00) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| SCHEMBL681575 | 0.81 | OPRM1 (0.72) | OPRM1OGFRL1OPRL1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11311504-B2 | Pharmaceutical composition comprising (1R,4R)-6′- fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro [cyclohexane-1,1′-pyrano- [3,4,b ]indol] -4-amine and paracetamol or propacetamol | PARK THERAPEUTICS, INC. (US) | 2022-04-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11311504-B2 | Pharmaceutical composition comprising (1R,4R)-6′- fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro [cyclohexane-1,1′-pyrano- [3,4,b ]indol] -4-amine and paracetamol or propacetamol | CYP2D6, CYP3A43, CYP2E1 | OPRM1 37/4885OPRL1 36/4885OPRD1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.